Print

EV03/ANRSVAC20

A Phase I/II Trial to Compare the Immunogenicity and Safety of 3 DNA C Prime Followed by 1 NYVAC C Boost to 2 DNA C Prime Followed by 2 NYVAC C Boost(EV03/ANRSVAC20)

Trial Details:

I/II Completed
French National Agency for Research on AIDS and viral hepatitis (ANRS), EuroVacc November 01, 2007
DNA-C,NYVAC-C Pox gag, pol, nef and env C; DNA Nef; Gag; Env; Pol C 97CN54
DNA-C DNA
NYVAC-C Viral Vector - Pox
France, Germany, Switzerland, United Kingdom 147
NCT00490074
http://clinicaltrials.gov/ct2/show/NCT00490074?term=EV+03&rank=1